Company / Operating Income per Share
Syndax Pharmaceuticals Inc Operating Income per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income per Share
-$3.19
FY2025
5-year range
-$4.00 / -$1.20
FY2021-FY2025
Trend
+20.4%
vs FY2024
Sector context
#142 of 201
Health Care
What the data says
At $-3.19, Syndax Pharmaceuticals Inc's operating income per share ranks #142 of 201 in the Health Care sector. Operating Income per Share returned to growth in FY2025 after 3 years of decline, reaching $-3.19.
Based on SEC 10-K filings.
-3.19 in FY2025.
Improved from $-3.38 to $-3.19 over the past 2 years.
Health Care sector context is included.
Operating Income per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#142 of 201 in Health CareTop 71% of 201This company -$3.19 Sector average -$28.56
▼
+88.8% above sector average
Key checks
Key Insights
- In FY2025, operating income per share increased 20.4% year-over-year.
- Ranks #142 out of 201 companies in the Health Care sector.
- Peak operating income per share was recorded in FY2017.
- Lowest operating income per share in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Income per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.19 | +20.4% |
| FY2024 | -$4.00 | -18.6% |
| FY2023 | -$3.38 | -22.3% |
| FY2022 | -$2.76 | -129.7% |
| FY2021 | -$1.20 | +57.0% |
| FY2020 | -$2.80 | -12.1% |
| FY2019 | -$2.49 | -39.0% |
| FY2018 | -$1.79 | -59.3% |
| FY2017 | -$1.13 | +99.5% |
| FY2016 | -$249.67 | +16.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026